How to Extend Your Startup Runway Without Giving Up Equity: The Australian Founder's Guide

By Alex Knight, Founder and CEO, Advanced

Runway is power. The more of it you have, the better your decisions get.

With 18 months of runway, you raise when you want to, at valuations that reflect the business you're building. With four months of runway, you raise because you have to. Investors know the difference. Every term sheet, every valuation cap, every dilutive concession reflects the negotiating position you walked in with.

The founders who consistently make good capital decisions aren't the ones who raise the most. They're the ones who extend their runway furthest, preserve the most equity, and arrive at every fundraise with options rather than pressure.

This guide is the complete framework for doing that in Australia. It covers the correct runway calculation, the four levers that actually move the number, and every non-dilutive tool available to Australian founders, including the one most people miss.

‍

Why Equity Is the Expensive Default

Founders reach for equity because it's familiar. Another round, another note, another angel. The mechanics are understood, the path is well-worn, and when a board asks "what's the plan for runway?" an equity raise is the answer that sounds like a plan.

The problem isn't that equity is wrong. The problem is that it's often the default rather than the decision. Founders raise equity to solve problems that aren't capital problems. They raise to bridge timing gaps that could be closed without touching the cap table. They raise six months of runway when they need three, at valuations that don't reflect the business they'll be in 90 days.

Equity is permanent. The dilution stays after the problem it solved has resolved. The investor who came in at a depressed valuation during a cashflow crunch holds equity at Series B, Series C, and exit. Forever reflecting the moment you were negotiating from pressure.

Every tool covered in this guide is designed to answer one question before equity: is this actually a capital problem, or is it a timing problem? If the capital already exists in a future receivable: an R&D Tax Incentive refund, a signed contract, a confirmed grant. The right tool almost never involves equity.

‍

The Correct Runway Calculation

The standard runway formula is cash on hand divided by net monthly burn. It's a starting point, not the answer.

For founders with eligible R&D spend, it systematically understates runway because it treats the R&D Tax Incentive refund as zero until the day it arrives. That refund is a committed receivable. The government has structured a program to pay it back at 43.5% of eligible spend for companies with aggregated turnover under $20 million. It accrues monthly. It belongs in the calculation.

The adjusted calculation:

Divide your expected annual R&D refund by 12 to get the monthly accrual. Subtract that from your net burn to get your adjusted net burn. Divide cash on hand by adjusted net burn to get adjusted runway. A company with $800,000 in the bank, $100,000 monthly gross burn, $20,000 monthly revenue, and $600,000 in annual eligible R&D spend:

• Standard net burn: $80,000
• Monthly refund accrual: $21,750 ($261,000 ÷ 12)
• Adjusted net burn: $58,250
• Standard runway: 10 months
• Adjusted runway: 13.7 months

Nearly four months of additional runway, without changing a single operational decision. The capital exists. The calculation was just wrong.

The full runway calculation guide covers this in depth, including how to present the adjusted number to your board alongside the standard figure.

‍

‍

The Four Levers for Extending Runway

Every runway extension strategy works through one or more of four levers. Understanding which lever you're pulling matters. Some are one-time fixes, some are structural, and some only work in combination.

Lever 1: Increase revenue velocity

Faster revenue collection reduces net burn without touching the cost base. Shorter payment terms, upfront annual contracts, reduced free trial periods. Each one pulls cash forward and extends the runway calculation without issuing a dollar of equity. For pre-revenue companies, this lever doesn't apply yet. For early-revenue companies, it's often the fastest lever to pull and the one with the lowest cost.

Lever 2: Access committed receivables early

This is the lever most founders don't know exists. If you have capital committed to you: an R&D Tax Incentive refund, a signed government grant awaiting disbursement, a confirmed contract with deferred payment. That capital is real. It's just stuck in a future payment. Accessing it early through the right instrument closes the timing gap without equity, without ongoing debt service, and without touching the cap table. R&D financing is the primary tool for this lever in Australia. It's covered in full in section 6.

Lever 3: Reduce burn strategically

Not all cost reduction is equal. For companies with eligible R&D spend, the decision about what to cut should factor in eligibility: payroll costs for roles engaged in eligible R&D activity generate a refund. Payroll costs for non-eligible roles don't. Protecting the R&D-eligible team and reducing non-eligible overhead maintains the refund pipeline while reducing gross burn. It's a structurally different decision than across-the-board headcount reduction.

The burn rate management guide covers how to apply this thinking to your specific cost base.

Lever 4: Non-dilutive capital injection

When the first three levers have been fully applied and runway is still insufficient, non-dilutive capital provides an injection without equity. Grants, revenue-based financing, venture debt, and R&D financing all operate here. Each one suits a different company profile and situation, covered in sections 6 and 7.

‍

The Dilutive vs Non-Dilutive Decision Framework

The most important question before any capital decision is whether the problem you're solving requires new capital or just earlier access to capital that already exists.

Capital problem: the money doesn't exist yet. You need to fund a new hire, a market entry, a product extension beyond what your current revenues or receivables can cover. The right tools are equity, venture debt, or revenue-based financing: instruments that bring in genuinely new capital.

Timing problem: the capital exists but it's stuck in a future payment. An R&D Tax Incentive refund. A confirmed grant awaiting disbursement. A signed customer contract with 60-day payment terms. The right tool is whichever instrument advances that receivable most cheaply, almost always without equity.

Most founders treat every cashflow problem as a capital problem. In practice, a significant proportion of early-stage runway pressure is a timing problem. Solving timing problems with permanent equity dilution is one of the most consistently expensive decisions in the startup lifecycle.

The complete dilutive vs non-dilutive framework covers how to diagnose which type of problem you're facing and which instrument matches it.

‍

The Seed to Series A Gap

The gap between Seed and Series A is where most runway pressure becomes acute. Seed capital is deployed. The build is largely done. The commercial metrics: predictable revenue, clear unit economics, a path to profitability. None of these are quite there yet for a Series A. The gap can be 6 to 18 months. Sometimes longer for companies with long development cycles.

This is the moment most cap tables get permanently damaged. A bridge round from a position of obvious need, at a valuation that reflects the pressure rather than the business, creates dilution that compounds at every subsequent round.

The founders who manage this gap well understand three things. First, the gap is structural, not a failure of planning. It exists because Seed rounds are sized to build, not to achieve Series A metrics. Second, the gap has a specific shape for founders with eligible R&D spend: capital spent, refund deferred, metrics not yet there. Third, the right tool for the gap depends entirely on what kind of problem it is.

The full guide to the Seed to Series A gap covers the five bridge options and the decision framework for each.

‍

R&D Financing: The Australian Advantage

Australia has a structural funding advantage that most other startup ecosystems don't: the R&D Tax Incentive. A government-backed program that commits to returning 43.5% of eligible R&D spend to companies with aggregated turnover under $20 million, regardless of profitability. That's real capital, accruing in real time, on the work founders are already doing.

The problem is timing. The refund doesn't arrive until after 30 June, after the claim is lodged, after the ATO processes it. Typically October to December at the earliest. For a company burning $80,000 per month with a $261,000 refund in the pipeline, that's three months of burn sitting in a government payment queue.

R&D financing resolves the timing. The facility is sized based on the anticipated refund, typically up to 80% of the expected amount. Capital lands in your account within days of approval. When the ATO refund arrives, it repays the facility in a single payment. No monthly repayments against cash during the facility period. No equity. No warrants. No personal guarantees.

The multiplier effect. Capital accessed before 30 June can be reinvested into eligible R&D before the financial year closes. That additional spend generates its own refundable offset. At 43.5%, every dollar reinvested in eligible R&D earns back 43 cents on the next claim. Early access isn't just a bridge. It's a mechanism for compounding the program's value.

Who qualifies. Any Australian company registered with AusIndustry as an R&D entity and spending on eligible experimental activities. Eligible work includes software development, hardware prototyping, clinical trials, field trials, materials research, and any work involving genuine technical uncertainty and systematic investigation. Revenue is not required. VC backing is not required.

What it costs. A financing fee at approximately 1.38% per month on the facility amount. On a $200,000 facility over six months, that's approximately $16,500. Compared to the permanent dilution of a bridge equity round at the same moment, the economics are almost always clear.

The complete R&D financing guide covers eligibility, the calculation, and how the process works.

‍

Other Non-Dilutive Options

R&D financing is the most relevant non-dilutive tool for eligible founders, but it's not the only one. Here's where the others fit.

Government grants

Non-dilutive, free when you get them, and genuinely useful for the right company at the right time. The Entrepreneurs' Programme, Accelerating Commercialisation, CRC grants, and export grants all provide capital without equity.

The constraint is time. Grant applications take months to assess and months more to disburse. For a company with six weeks of runway, a grant application started today will not help. Grants are a proactive runway extension tool, not a reactive bridge.

Revenue-based financing

Advances capital against future recurring revenue. Repaid as a percentage of monthly revenue until the advance plus a fee is settled. No equity, no fixed monthly payment. Works well for SaaS companies with 6-12 months of consistent monthly recurring revenue. Doesn't work for pre-revenue companies or companies with lumpy revenue, which includes most early-stage companies with significant R&D spend.

Venture debt

A term loan for VC-backed companies, typically offered alongside or after an equity raise. Comes with monthly repayments and usually includes warrants: small equity stakes representing 0.5-2% of the loan in equity value. Works well when you've just closed an equity round and want to extend runway without further dilution. Requires a VC lead, revenue traction, and the ability to service monthly repayments against your cash position.

The R&D financing vs venture debt comparison covers how to choose between the two when both are available.

Bridge rounds

Convertible notes and SAFEs from existing or new investors. They are dilutive. They convert into equity at the next qualified round, often with a discount and a valuation cap that makes the effective dilution larger than it appears at signing. Right when you have a genuine capital problem that the other tools can't solve, and supportive existing investors willing to extend. Wrong when what you actually have is a timing problem.

‍

Putting It Together: The Decision Framework

Before any capital decision, work through these four questions in order.

Is this a capital problem or a timing problem?
If the capital exists in a future receivable, the answer is almost never equity. Access the receivable.

Which lever applies?
Revenue velocity, receivables access, burn reduction, or new capital injection. Most runway crunches are solved by pulling two levers together rather than one.

How long do you actually need?
Be precise. If you need four months to hit a Series A metric, a four-month solution is all you need. Every additional month of bridge capital has a cost: in interest, in dilution, or in both.

What does this cost at the next valuation?
Model the cap table impact of any dilutive instrument at three scenarios: your target valuation, 30% below target, and at the valuation cap on any note. The outcomes in each scenario are often more different than the term sheet implies.

‍